Foundations Investment Advisors LLC Has $445,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Foundations Investment Advisors LLC decreased its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 9.9% in the 3rd quarter, Holdings Channel reports. The firm owned 102,300 shares of the company’s stock after selling 11,250 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Black Diamond Therapeutics were worth $445,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Susquehanna Fundamental Investments LLC bought a new position in Black Diamond Therapeutics during the first quarter worth $82,000. Acadian Asset Management LLC raised its position in shares of Black Diamond Therapeutics by 13.8% in the 1st quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after acquiring an additional 20,616 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $108,000. Bank of New York Mellon Corp bought a new stake in shares of Black Diamond Therapeutics during the 2nd quarter valued at about $508,000. Finally, Rhumbline Advisers grew its stake in Black Diamond Therapeutics by 10,334.3% during the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after purchasing an additional 46,401 shares during the period. 95.47% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BDTX shares. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a report on Tuesday, October 8th. Piper Sandler increased their target price on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, October 9th. Finally, Raymond James started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price objective on the stock.

Black Diamond Therapeutics Stock Down 2.0 %

Shares of NASDAQ:BDTX opened at $2.98 on Friday. The stock’s 50 day moving average is $4.73 and its 200-day moving average is $5.16. Black Diamond Therapeutics, Inc. has a twelve month low of $1.62 and a twelve month high of $7.66. The firm has a market capitalization of $167.63 million, a price-to-earnings ratio of -1.80 and a beta of 2.47.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Equities research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.44 earnings per share for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.